SynthesisActa neurochirurgica2025
Intracranial manifestations of adult Rosai-Dorfman disease: a systematic review and IPD meta-analysis of 327 cases.
Synthesis in Acta neurochirurgica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosai-Dorfman disease (RDD) is a rare non-Langerhans histiocytosis that involves the central nervous system (CNS) in approximately 5% of cases, most often presenting intracranially. While pediatric cases have been reported more frequently, adult intracranial RDD (IC-RDD) remains poorly characterized. We conducted a systematic review and individual patient data meta-analysis in accordance with PRISMA guidelines to define the epidemiology, clinical presentation, pathology, management strategies, and outcomes of adult IC-RDD. PubMed, Scopus, and the Cochrane Library were searched for histologically confirmed cases in adults over 18 years, and case reports, case series, and observational studies were included. Data were extracted on demographics, symptoms, imaging, histopathology, treatment, and outcomes. Primary endpoints were recovery and recurrence-free survival (RFS), with risk ratios (RRs) and 95% confidence intervals (CIs) calculated using random-effects models. A total of 327 patients from 186 studies met inclusion criteria. The median age was 43.6 years (range 18-83), with a male predominance (70.9%). The most common symptoms were headache (35.2%), seizures or loss of consciousness (28.7%), and visual disturbance (26.9%). Lesions were typically supratentorial intra-axial (52.9%) or extra-axial (20.5%). Surgical intervention was performed in 93.6% of patients, with gross total resection (GTR) achieved in 45.3%. At a median follow-up of 18.8 months, 37.9% achieved full recovery, 46.8% partial recovery, and 15.3% experienced recurrence, with a median RFS of 12 months. GTR was strongly associated with improved recovery (RR 0.26, 95% CI 0.19-0.37), whereas supratentorial intra-axial location (RR 0.56, 95% CI 0.41-0.75) and perilesional edema (RR 0.65, 95% CI 0.47-0.89) predicted poorer outcomes. These findings indicate that adult IC-RDD predominantly affects middle-aged men, presents with mass-effect symptoms, and has a location-dependent prognosis, with GTR conferring the best chance of recovery but recurrence remaining common and underscoring the need for long-term surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.